Help paying · Medicare negotiated price · pharmacy cost · cycle 2026
Januvia (sitagliptin): where help paying exists, what Medicare negotiated and what pharmacies pay
1 assistance program lists sitagliptin, each with its income ceiling and when we read it. Medicare's negotiated price for a 30-day supply is $113 (in force since January 1, 2026). A scheduled change takes it to $116 on January 1, 2027. Per unit, the negotiated price is 37% of NADAC, the pharmacy acquisition benchmark. ClinicalTrials.gov lists 13 recruiting trials that name sitagliptin.
One package, side by side
Price per unit for one package of Januvia. The negotiated price applies to Medicare Part D; NADAC is a survey of what retail pharmacies pay to buy the drug.
Swipe to read across
Every package we can price
Per-unit prices (per each unit, as the files state). "Scheduled" is a price the CMS file already dates for the future.
| NDC | Product | Unit | Negotiated now | Scheduled | NADAC | Share |
|---|---|---|---|---|---|---|
| 00006-0112-01 | JANUVIA 50MG TABLET INNER PACK | EA | $3.91 | $4.01 | $10.55 | 37% |
| 00006-0112-28 | JANUVIA 50MG TABLET 100UU | EA | $3.91 | $4.01 | $10.55 | 37% |
| 00006-0112-31 | JANUVIA 50MG TABLETS 30UU | EA | $3.91 | $4.01 | $10.55 | 37% |
| 00006-0112-54 | JANUVIA 50MG TABLETS 90UU | EA | $3.91 | $4.01 | $10.55 | 37% |
| 00006-0221-01 | JANUVIA 25MG TABLET 100UU INNER PACK | EA | $3.91 | $4.01 | $10.54 | 37% |
| 00006-0221-28 | JANUVIA 25MG TABLET 100UU | EA | $3.91 | $4.01 | $10.54 | 37% |
| 00006-0221-31 | JANUVIA 25MG TABLETS 30UU | EA | $3.91 | $4.01 | $10.54 | 37% |
| 00006-0221-54 | JANUVIA 25MG TABLETS 90UU | EA | $3.91 | $4.01 | $10.54 | 37% |
| 00006-0277-01 | JANUVIA 100MG TABLET INNER PACK | EA | $3.91 | $4.01 | $10.55 | 37% |
| 00006-0277-02 | JANUVIA 100 MG TABLET 30 CT CALENDAR PACK | n/a | $3.91 | $4.01 | n/a | no NADAC price |
| 00006-0277-14 | (name not listed) | n/a | $3.91 | $4.01 | n/a | no NADAC price |
| 00006-0277-27 | (name not listed) | n/a | $3.91 | $4.01 | n/a | no NADAC price |
| 00006-0277-28 | JANUVIA 100MG TAB 100UD | EA | $3.91 | $4.01 | $10.55 | 37% |
| 00006-0277-30 | (name not listed) | n/a | $3.91 | $4.01 | n/a | no NADAC price |
| 00006-0277-31 | JANUVIA 100MG TABLET 30UU | EA | $3.91 | $4.01 | $10.55 | 37% |
| 00006-0277-33 | JANUVIA TABLET 100 MG | n/a | $3.91 | $4.01 | n/a | no NADAC price |
| 00006-0277-54 | JANUVIA 100MG TABLET 90UU | EA | $3.91 | $4.01 | $10.55 | 37% |
| 00006-0277-74 | (name not listed) | n/a | $3.91 | $4.01 | n/a | no NADAC price |
| 00006-0277-82 | JANUVIA 100MG TAB 1000UD | EA | $3.91 | $4.01 | $10.55 | 37% |
When could a generic arrive
Each date below is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
| Application | Product | Latest listed patent expiry | Latest listed exclusivity expiry | Latest of the two | Set by |
|---|---|---|---|---|---|
| NDA021995 | Januvia 100 Mg Tablet 30 Ct Calendar Pack, Januvia 100mg Tab 1000ud, Januvia 100mg Tab 100ud, Januvia 100mg Tablet 30uu and 8 more | May 24, 2027 | none listed | May 24, 2027 | patent 7326708 with its pediatric extension; 6 dated entries listed |
Source: FDA Orange Book data files, edition September 2026, read November 7, 2026; patent listings are as submitted by applicants and not verified by FDA. FDA data file.
Medicare Part D spending
CMS's Medicare Part D spending dataset reports gross spending on Januvia of $3.81 billion in 2024, across 4,027,317 claims and 828,288 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
| Year | Gross spending | Claims | Beneficiaries | Average spending per claim |
|---|---|---|---|---|
| 2024 | $3.81 billion | 4,027,317 | 828,288 | $946 |
| 2023 | $4.09 billion | 4,029,094 | 843,391 | $1,015 |
| 2022 | $4.10 billion | 4,242,641 | 884,825 | $966 |
| 2021 | $4.06 billion | 4,507,803 | 934,542 | $901 |
| 2020 | $3.87 billion | 4,664,181 | 934,686 | $829 |
Source: CMS Medicare Part D spending by drug (data-year-2024, modified 2026-06-25), read November 7, 2026. CMS dataset page. All manufacturers combined; the figures are a drug-level aggregate of claims and say nothing about a formulary or coverage.
FDA safety program (REMS)
- Januvia (application NDA021995): listed as released, without Elements to Assure Safe Use. Program dated February 26, 2010, last modified April 14, 2011. REMS@FDA program page.
A REMS is a safety program the FDA can require for a drug. Some restrict how it is prescribed or dispensed, for example through certified prescribers or pharmacies. This lists what the FDA's REMS@FDA files tie to the application; it does not say which prescribers or pharmacies take part, or whether a given patient needs the program.
Source: FDA REMS@FDA data files (rems-fda-files-2026-11-07-products-20a9945448dd), read November 7, 2026. REMS@FDA product file.
Rare-disease (orphan) designations
The FDA's orphan drug database lists 1 designation for sitagliptin. A designation is not an approval and not a statement that the drug treats the condition; the status column is the database's own.
| Designated | Designated use | Status | Sponsor |
|---|---|---|---|
| January 15, 2026 | treatment of Duchenne muscular dystrophy | Designated | Revio Therapeutics LLP |
Source: FDA Orphan Drug Designations and Approvals database, read November 7, 2026. FDA orphan drug search.
Medicaid use by state
CMS's State Drug Utilization Data records, for 2025, how many prescriptions each state's Medicaid program paid for under this drug's packages and what it reimbursed. The 10 states with the largest reimbursement are shown of 12 with data. Reimbursement is before the rebates manufacturers pay states, so it is not a net cost and not a price a patient pays.
| State | Medicaid-paid prescriptions | Medicaid reimbursed | Covers |
|---|---|---|---|
| KS | 131 | $38,394 | All record types |
| CO | 96 | $34,994 | Fee-for-service only |
| SC | 73 | $34,890 | Fee-for-service only |
| OK | 62 | $33,764 | Fee-for-service only |
| NV | 73 | $31,210 | Fee-for-service only |
| MN | 90 | $29,044 | Fee-for-service only |
| VA | 60 | $25,864 | All record types |
| AL | 65 | $21,645 | All record types |
| AK | 86 | $20,360 | Fee-for-service only |
| MT | 48 | $18,608 | All record types |
Where the publisher suppresses small managed-care cells, a state's figure covers fee-for-service claims only and understates use (6 state and package figures are marked that way here). A state missing from the table means its figures were suppressed or not reported, not zero use. 306 older-year figures are held and left out of the table.
Source: CMS State Drug Utilization Data (State Drug Utilization Data 2025, modified 2026-07-13T15:28:32Z), read November 7, 2026. CMS dataset page. State-reported data compiled by CMS; aggregate by state and package, no provider or patient data.
Where help paying exists
Programs in our finder that list sitagliptin. Each shows its income ceiling, when we read it and whether we checked it against the program's own document. Eligibility is decided by the program, not by us.
- Merck Helps (Merck Patient Assistance Program) manufacturer
Income at or below $79,800 for one person for KEYTRUDA, or $63,840 for JANUVIA and JANUMET
Check where your income sits against each ceiling: open the assistance finder. See what has changed and when we last verified each program on the program status board.
Label changes
The FDA file lists no non-manufacturing label change for these applications since November 11, 2025. The most recent one it lists is dated June 21, 2022 (Labeling).
Source: FDA Drugs@FDA data file, read November 7, 2026. Dates are the FDA action dates; the documents are on FDA's own site. FDA data file. All recent changes across these drugs: label changes feed.
Clinical trials recruiting
ClinicalTrials.gov lists 13 interventional trials that name sitagliptin and are recruiting, and 5 more not yet recruiting. By phase: Phase 4: 4, PHASE1/PHASE2: 3, Phase 2: 2, Phase 1: 2, Phase 3: 1, Not applicable: 1. The 10 most recently updated are below. A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
| Trial | Title and conditions | Phase | Lead sponsor | Last updated | Countries |
|---|---|---|---|---|---|
| NCT07675174 | PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCTGVHD - Graft-Versus-Host Disease | Phase 1 / Phase 2 | Northwell Health | November 6, 2026 | United States |
| NCT07436663 | Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DICBreast Cancer | Phase 4 | Tanta University | October 15, 2026 | Egypt |
| NCT07003542 | A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 GliomasGlioblastoma; Brain Tumor | Phase 2 | Case Comprehensive Cancer Center | August 6, 2026 | United States |
| NCT07634380 | Sitagliptin With Pembro in RCC and MelanomaAdvanced Renal Cell Carcinoma; Advanced Melanoma | Phase 1 | Fernando Maciel Barbosa | July 30, 2026 | United States |
| NCT07717242 | Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder CancerBladder Urothelial Carcinoma; Bladder Cancer | Phase 2 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | July 21, 2026 | China |
| NCT07711171 | Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive ImpairmentType 2 Diabetes Mellitus; Cognitive Impairment | Phase 4 | Fudan University | July 17, 2026 | China |
| NCT07541781 | Sitagliptin in Recurrent/Progressive Grade 4 GliomaGlioma; Glioblastoma; Recurrent Glioma | Phase 1 | Kailin Yang, MD, PhD | June 17, 2026 | United States |
| NCT07365592 | Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRCColorectal Cancer | Phase 1 / Phase 2 | Second Affiliated Hospital, Zhejiang University, School of Medicine | May 13, 2026 | China |
| NCT06246799 | Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset DiabetesType 2 Diabetes (Adult Onset) | Phase 3 | The University of Texas Health Science Center at San Antonio | March 10, 2026 | United States |
| NCT07374328 | Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes MellitusType 2 Diabetes | Phase 1 / Phase 2 | Second Affiliated Hospital of Guangzhou Medical University | January 28, 2026 | China |
Source: ClinicalTrials.gov, registry data processed November 6, 2026, summarized and trimmed by OmniRx. Search on ClinicalTrials.gov.
Questions
What is the Medicare negotiated price of Januvia?
For a 30-day supply the price CMS published is $113, in force since January 1, 2026. The CMS file also schedules $116 from January 1, 2027. This is a price CMS agreed with the manufacturer for Medicare Part D, not what a person pays at the counter.
How does the negotiated price compare with what pharmacies pay?
Across the 13 packages where both CMS files give a price per unit, the median negotiated price is 37% of NADAC, the pharmacy acquisition benchmark (NADAC as of November 4, 2026). NADAC is a survey average, not a quote.
Is there help paying for Januvia?
1 assistance program lists it in our finder. Eligibility depends on income, coverage and the program's current rules; each program's own page decides.
When could a generic version of Januvia arrive?
For Januvia, the FDA's Orange Book (edition September 2026) lists these latest patent or exclusivity expiry dates by application: NDA021995, May 24, 2027. Each date is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
Can I join a clinical trial for Januvia?
ClinicalTrials.gov lists 13 recruiting interventional trials that name sitagliptin (registry data processed November 6, 2026). A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
How much does Medicare Part D spend on Januvia?
CMS's Medicare Part D spending dataset reports gross spending on Januvia of $3.81 billion in 2024, across 4,027,317 claims and 828,288 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
For developers: this drug as data
One call returns price, generic-entry upper bound, label history, recalls, trials, assistance, and where facts exist the FDA safety program (REMS), DEA schedule, orphan designations, safety notices and Medicaid use by state, each with receipts.
Example file: https://omnirx.org/api/v1/dossier/januvia.json
The licence page sets out what a data licence covers, and the API page documents these files.
Evaluation files with receipts; contract may change; not clinical advice.
Sources and terms. CMS Medicare Drug Price Negotiation Program data file (read November 6, 2026; the CMS page states no licence or restriction); CMS NADAC from data.medicaid.gov under the labels in the OmniRx licence ledger; program details read from each program's own pages; CMS Medicare Part D spending by drug; FDA Drugs@FDA and Orange Book data files; ClinicalTrials.gov registry data. Figures are stored with their sources in the OmniRx library (edition 2026-11). Free to cite with attribution. Not medical, legal or financial advice. Report an error through the contact page. Licence the data.